Abstract:Understanding the perturbed lung immune cell distribution and their functionality in tuberculosis is well documented; however, limited reports covered their disruption, if any, in diabetes-tuberculosis (DM-TB) comorbid conditions. Here, we measured serum cytokines and employed single-cell RNA-seq to investigate the molecular mechanisms that govern the heterogeneity in host immune response in DM TB comorbid conditions. Diabetes associated with chronic hyperinflammation and reduced lung infiltrating immune cells delayed the immune response to Mycobacterial infection. scRNA-seq of lung CD3+ and CD11c+ cells revealed compromised adaptive and innate immunity, with decreased Th1 and M1 macrophage populations in DM-TB mice. A dampened immune response, marked by increased IL-16 signaling and reduced TNF and IFN-II responses observed in DM-TB. This study highlights chronic inflammation, hyperglycemia, and dyslipidemia associated with diabetes impairing anti-TB immunity, and selective inhibition of aberrant IL-16 secretion and Th17 cell activation might provide strategies for better management of this comorbidity.

What problem does this paper attempt to address?

This paper attempts to solve the problem of the distribution and functional disorder of pulmonary immune cells under the condition of diabetes - tuberculosis comorbidity (DM - TB). Specifically, the main research questions include: 1. **Understanding the impact of diabetes on the immune response to tuberculosis**: - Does diabetes change the host's immune response to Mycobacterium tuberculosis (Mtb) infection? - Are there specific immune cell subsets and molecular mechanisms in diabetic patients that lead to impaired anti - tuberculosis immunity? 2. **Exploring the immunological heterogeneity under the condition of diabetes - tuberculosis comorbidity**: - Through single - cell RNA sequencing (scRNA - seq), study the immune landscape of CD3⁺ and CD11c⁺ cells in the lungs of diabetes and diabetes - tuberculosis comorbidity mouse models. - Reveal the changes in the transcriptional regulatory network of these cells under the condition of diabetes and tuberculosis comorbidity. 3. **Evaluating the impact of diabetes on the pathological progression of tuberculosis**: - Does diabetes cause a delay or weakening of the immune response in tuberculosis patients? - Does diabetes increase the tissue damage and inflammatory response of tuberculosis? 4. **Identifying potential treatment targets**: - Can the management of diabetes - tuberculosis comorbidity be improved by inhibiting abnormal IL - 16 secretion and Th17 cell activation? ### Key findings - **Hyper - inflammatory state**: Diabetic mice exhibit higher levels of serum IL - 6, TNF - α and IL - 17A, reflecting a chronic hyper - inflammatory state. - **Reduced immune cell infiltration**: There are fewer CD3⁺ cells infiltrating the lungs of diabetes - tuberculosis (DM - TB) mice, indicating a delayed immune response. - **Weakened immune response**: DM - TB mice show a weaker pro - inflammatory response, decreased Th1/CD4 CTL activity, and increased Th17 - driven tissue damage. - **Transcriptional regulation changes**: scRNA - seq analysis shows that there are extensive transcriptional regulation changes in the pulmonary immune cells of diabetic and DM - TB mice, especially an increase in the proportion of Th17 cells and naive T cells. - **Signal pathway alterations**: The MIF and IL - 16 signal pathways are significantly enriched in diabetic mice, indicating an enhanced basal inflammatory state. ### Conclusion This study shows that diabetes impairs anti - tuberculosis immunity through chronic inflammation, hyperglycemia and dyslipidemia. Selective inhibition of abnormal IL - 16 secretion and Th17 cell activation may be an effective strategy to improve the management of diabetes - tuberculosis comorbidity. This research provides an important immunological basis for in - depth understanding of diabetes - tuberculosis comorbidity and new directions for future treatment interventions.

Diabetes-Tuberculosis Comorbidity Characterized by Reduced Type-II Interferon and Elevated Th17 Responses.